Brown Advisory Inc Contrafect Corp Transaction History

Brown Advisory Inc

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$0.18 - $3.51 $2,988 - $58,266	-16,600 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$5.5 - $12.3 $91,300 - $204,180	16,600 New	16,600 $96,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

Stay updated on Brown Advisory Inc with notifications on news.